<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859882</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol PERCAF 2018</org_study_id>
    <nct_id>NCT03859882</nct_id>
  </id_info>
  <brief_title>Protocol PERCAF 2018</brief_title>
  <acronym>PERCAF</acronym>
  <official_title>Polymorphisms and Efficiency of Caffeine on Performances During Total Sleep Deprivation un Healthy Subject. Multicentric, Versus Placebo, Randomised, Cross Over, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche Biomedicale des Armees</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherche Biomedicale des Armees</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicentric controlled study, we aims to evaluate effect of caffeine on mental&#xD;
      performances during a sleep deprivation protocol. Genetic polymorphisms are considered as a&#xD;
      covariable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coffee is the most consumed arousing substance in the world. Caffeine is used as a natural&#xD;
      countermeasure to maintain the performance of sleep deprived subjects. However, the&#xD;
      effectiveness of caffeine is characterized by a large individual variability, also observed&#xD;
      on side effects. This variability could notably be related to polymorphisms of the adenosine&#xD;
      receptor 2a gene (ADORA2A) and Tumor Necrosis Factor-alpha, a pro-inflammatory cytokine whose&#xD;
      increase is observed during sleep deprivation.&#xD;
&#xD;
      This study, under conditions of total sleep deprivation in the laboratory (40 hours of&#xD;
      continuous awakening), examine the cross-influence of two polymorphisms (ADORA2A: rs5751876&#xD;
      and TNF-alpha: rs1800629) on the sensitivity to caffeine and on the degradation of&#xD;
      attentional performances. Physical performance, mental performance, immuno-inflammatory&#xD;
      responses and the occurrence indesirable effects will be evaluate.&#xD;
&#xD;
      This work aims to understand the mechanisms that contribute to increasing individual&#xD;
      vulnerability and promoting protective countermeasures. The purpose of this project is to&#xD;
      improve the recommendations concerning the daily use of caffeine and during periods of&#xD;
      prolonged awakening, particularly in the military environment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2018</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychomotor vigilance test Speed</measure>
    <time_frame>Change from Baseline Psychomotor vigilance test Speed at day 2 after 24 hours awaking</time_frame>
    <description>Speed at the Psychomotor vigilance test test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>Change from Baseline at day 2 after 25 hours awaking</time_frame>
    <description>Number of errors at executive performance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Force -velocity</measure>
    <time_frame>Change from Baseline at day 2 after 32 hours awaking</time_frame>
    <description>Power at the force-velocity test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Sleep</condition>
  <condition>Caffeine</condition>
  <condition>Polymorphism</condition>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>in 2 administration (08:00 and 14:00) per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sleep deprivation</intervention_name>
    <description>40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).</description>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment&#xD;
&#xD;
          -  History of cardiovascular, psychiatric, pneumologic, haematologic, cancerology disease&#xD;
&#xD;
          -  Nonvoluntary&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut de recherche biomedical des armées</name>
      <address>
        <city>Brétigny-sur-Orge</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep deprivation</keyword>
  <keyword>cognition</keyword>
  <keyword>attention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

